Cost of Revenue Comparison: Veracyte, Inc. vs Bausch Health Companies Inc.

Bausch vs. Veracyte: A Decade of Cost Dynamics

__timestampBausch Health Companies Inc.Veracyte, Inc.
Wednesday, January 1, 2014225460000016606000
Thursday, January 1, 2015264500000021497000
Friday, January 1, 2016261100000025462000
Sunday, January 1, 2017254800000028195000
Monday, January 1, 2018235100000033078000
Tuesday, January 1, 2019235000000036523000
Wednesday, January 1, 2020224900000041455000
Friday, January 1, 2021239400000074400000
Saturday, January 1, 20222364000000101582000
Sunday, January 1, 20232559000000112903000
Loading chart...

Unleashing the power of data

Cost of Revenue: A Tale of Two Companies

In the ever-evolving landscape of the healthcare industry, understanding the cost dynamics of companies is crucial. Over the past decade, Bausch Health Companies Inc. and Veracyte, Inc. have showcased contrasting trajectories in their cost of revenue. Bausch Health, a giant in the pharmaceutical sector, consistently reported costs exceeding $2 billion annually, reflecting its expansive operations. In contrast, Veracyte, a leader in genomic diagnostics, has seen its cost of revenue grow from approximately $17 million in 2014 to over $112 million in 2023, marking a staggering increase of over 560%. This growth underscores Veracyte's expanding market presence and investment in innovation. As we delve into these figures, it becomes evident that while Bausch Health maintains a steady course, Veracyte is on a rapid ascent, reshaping its financial landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025